title: Weight-based ribavirin with pegylated interferon alfa 2b: benefits, risks, and the origin of the evidence.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Hrachovec
authors.forename: Pallavi
authors.initials: P
authors.lastname: Patel
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D001835:Body Weight; D004359:Drug Therapy, Combination; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008103:Liver Cirrhosis / Q000188:drug therapy*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin